Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation?
AI Sentiment
Positive
6/10
as of 12-05-2025 3:40pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 207.1M | IPO Year: | 2021 |
| Target Price: | $70.43 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -431.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $65.80 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director, 10% Owner
Avg Cost/Share
$25.12
Shares
24,579
Total Value
$617,424.48
Owned After
779,652
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$25.22
Shares
251,518
Total Value
$6,343,283.96
Owned After
779,652
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$27.64
Shares
124,311
Total Value
$3,408,229.74
Owned After
779,652
Director, 10% Owner
Avg Cost/Share
$28.12
Shares
90,941
Total Value
$2,557,260.92
Owned After
779,652
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$28.01
Shares
53,345
Total Value
$1,494,193.45
Owned After
779,652
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$28.01
Shares
76,880
Total Value
$2,153,408.80
Owned After
779,652
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$28.11
Shares
25,027
Total Value
$703,508.97
Owned After
779,652
SEC Form 4
10% Owner
Avg Cost/Share
$30.08
Shares
200
Total Value
$6,015.00
Owned After
1,166,909
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$29.88
Shares
92,023
Total Value
$2,730,483.09
Owned After
779,652
10% Owner
Avg Cost/Share
$30.05
Shares
11,616
Total Value
$349,101.46
Owned After
1,166,909
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 30, 2025 | Sell | $25.12 | 24,579 | $617,424.48 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 29, 2025 | Sell | $25.22 | 251,518 | $6,343,283.96 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 28, 2025 | Sell | $27.64 | 124,311 | $3,408,229.74 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 27, 2025 | Sell | $28.12 | 90,941 | $2,557,260.92 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 24, 2025 | Sell | $28.01 | 53,345 | $1,494,193.45 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 23, 2025 | Sell | $28.01 | 76,880 | $2,153,408.80 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 21, 2025 | Sell | $28.11 | 25,027 | $703,508.97 | 779,652 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 21, 2025 | Sell | $30.08 | 200 | $6,015.00 | 1,166,909 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 20, 2025 | Sell | $29.88 | 92,023 | $2,730,483.09 | 779,652 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 20, 2025 | Sell | $30.05 | 11,616 | $349,101.46 | 1,166,909 |
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
6/10
See how VOR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.